Follow
Frank Gibbons
Frank Gibbons
Scientific Director, Takeda
Verified email at takeda.com
Title
Cited by
Cited by
Year
Towards a proteome-scale map of the human protein–protein interaction network
JF Rual, K Venkatesan, T Hao, T Hirozane-Kishikawa, A Dricot, N Li, ...
Nature 437 (7062), 1173-1178, 2005
35392005
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
AE Tron, MA Belmonte, A Adam, BM Aquila, LH Boise, E Chiarparin, ...
Nature communications 9 (1), 5341, 2018
4522018
Judging the quality of gene expression-based clustering methods using gene annotation
FD Gibbons, FP Roth
Genome research 12 (10), 1574-1581, 2002
4362002
Intensity-based protein identification by machine learning from a library of tandem mass spectra
JE Elias, FD Gibbons, OD King, FP Roth, SP Gygi
Nature biotechnology 22 (2), 214-219, 2004
3892004
A critical assessment of Mus musculusgene function prediction using integrated genomic evidence
L Peña-Castillo, M Tasan, CL Myers, H Lee, T Joshi, C Zhang, Y Guan, ...
Genome biology 9, 1-19, 2008
2972008
Predicting protein complex membership using probabilistic network reliability
S Asthana, OD King, FD Gibbons, FP Roth
Genome research 14 (6), 1170-1175, 2004
2712004
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
EK Keeton, K McEachern, KS Dillman, S Palakurthi, Y Cao, MR Grondine, ...
Blood, The Journal of the American Society of Hematology 123 (6), 905-913, 2014
2652014
Combining guilt-by-association and guilt-by-profiling to predict Saccharomyces cerevisiaegene function
W Tian, LV Zhang, M Taşan, FD Gibbons, OD King, J Park, Z Wunderlich, ...
Genome biology 9, 1-21, 2008
1122008
Genomewide Identification of Sko1 Target Promoters Reveals a Regulatory Network That Operates in Response to Osmotic Stress in Saccharomyces cerevisiae
M Proft, FD Gibbons, M Copeland, FP Roth, K Struhl
Eukaryotic Cell 4 (8), 1343-1352, 2005
912005
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
CM Patterson, SB Balachander, I Grant, P Pop-Damkov, B Kelly, ...
Communications Biology 4 (1), 112, 2021
762021
Chipper: discovering transcription-factor targets from chromatin immunoprecipitation microarrays using variance stabilization
FD Gibbons, M Proft, K Struhl, FP Roth
Genome biology 6, 1-9, 2005
692005
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
SB Balachander, SW Criscione, KF Byth, J Cidado, A Adam, P Lewis, ...
Clinical Cancer Research 26 (24), 6535-6549, 2020
502020
Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of nonsmall cell lung cancer …
RA Ward, MJ Anderton, P Bethel, J Breed, C Cook, EJ Davies, A Dobson, ...
Journal of medicinal chemistry 62 (24), 11004-11018, 2019
502019
An en masse phenotype and function prediction system for Mus musculus
M Taşan, W Tian, DP Hill, FD Gibbons, JA Blake, FP Roth
Genome biology 9, 1-16, 2008
342008
SILVER helps assign peptides to tandem mass spectra using intensity-based scoring
FD Gibbons, JE Elias, SP Gygi, FP Roth
Journal of the American Society for Mass Spectrometry 15, 910-912, 2004
292004
Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
B Schoeberl, B Harms, FD Gibbons, JB Fitzgerald, MD Onsum, U Nielsen, ...
US Patent App. 12/707,521, 2011
262011
FuncBase: a resource for quantitative gene function annotation
JE Beaver, M Taşan, FD Gibbons, W Tian, TR Hughes, FP Roth
Bioinformatics 26 (14), 1806-1807, 2010
182010
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor …
V Flemington, EJ Davies, D Robinson, LC Sandin, O Delpuech, P Zhang, ...
Molecular cancer therapeutics 20 (2), 238-249, 2021
162021
Mixture dynamics: combination therapy in oncology
J Gabrielsson, FD Gibbons, LA Peletier
European Journal of Pharmaceutical Sciences 88, 132-146, 2016
162016
MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells …
A Huhalov, S Adams, V Paragas, S Oyama, R Overland, L Luus, ...
Cancer Research 70 (8_Supplement), 3485-3485, 2010
162010
The system can't perform the operation now. Try again later.
Articles 1–20